304 related articles for article (PubMed ID: 22040998)
1. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
Chen YX; Li Y; Zhang LY; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
3. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
Chen E; Mullally A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
[TBL] [Abstract][Full Text] [Related]
4. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
[TBL] [Abstract][Full Text] [Related]
5. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
Ayad MW; Nafea D
Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
[TBL] [Abstract][Full Text] [Related]
6. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
7. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
8. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
Liu L; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
[TBL] [Abstract][Full Text] [Related]
9. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
[TBL] [Abstract][Full Text] [Related]
10. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
12. The JAK2 mutation.
Merchant S
Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
[TBL] [Abstract][Full Text] [Related]
13. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
Chen YX; Li Y; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
15. A role for JAK2 mutations in myeloproliferative diseases.
Morgan KJ; Gilliland DG
Annu Rev Med; 2008; 59():213-22. PubMed ID: 17919086
[TBL] [Abstract][Full Text] [Related]
16. [Application of genetic data to clinical practice of MPN].
Edahiro Y
Rinsho Ketsueki; 2015 Aug; 56(8):949-55. PubMed ID: 26345552
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
18. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
19. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
[TBL] [Abstract][Full Text] [Related]
20. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
